SOCM
SR One Capital Management Portfolio holdings
AUM
$461M
This Quarter Return
+34.93%
1 Year Return
+23.25%
3 Year Return
+188.96%
5 Year Return
–
10 Year Return
–
AUM
$274M
AUM Growth
+$274M
(+25%)
Cap. Flow
+$34.9M
Cap. Flow
% of AUM
12.74%
Top 10 Holdings %
Top 10 Hldgs %
100%
Holding
5
New
1
Increased
1
Reduced
–
Closed
–
Top Buys
| 1 |
ARS Pharmaceuticals
SPRY
|
$25.7M |
| 2 |
Design Therapeutics
DSGN
|
$9.23M |
Top Sells
No sells this quarter
Sector Composition
| 1 | Healthcare | 100% |
| Name | Market Value | Portfolio Weight | Shares or Principal |
Shares Change % | Capital Flow | |
|---|---|---|---|---|---|---|
1
Arcellx
ACLX
$3.85B
| $170M | 62.2% |
5,500,007
| – | – |
|
|
2
Design Therapeutics
DSGN
$315M
| $67M | 24.44% |
6,526,476
+900,000
| +16% | +$9.23M |
|
|
3
ARS Pharmaceuticals
SPRY
$1.15B
| $25.7M | 9.37% |
+3,009,677
| New | +$25.7M |
|
4
Nkarta
NKTX
$151M
| $7.99M | 2.92% |
1,333,333
| – | – |
|
|
EFTR
5
DELISTED
eFFECTOR Therapeutics, Inc. Common Stock
EFTR
| $2.93M | 1.07% |
6,822,114
| – | – |
|